Company profile
ACRIVON THERAPEUTICS, INC.
NASDAQ:ACRVBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05548296 | phase2 | recruiting | 2022-08-29 | 2027-05-30 | Acrivon Therapeutics | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma |
| NCT06667141 | phase1_2 | recruiting | 2024-10-08 | 2027-08-12 | Acrivon Therapeutics | Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors |
FDA applications (0)
No records yet.